EU regulator recommends revoking approval for Novartis’ sickle cell disease drug
The EMA’s human medicines committee concluded that the benefits of Adakveo did not outweigh its risks
Read More
Tag: Adakveo
NICE turns down Novartis’ Adakveo
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
Read More
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
